Clinical Trials Logo

Chemotherapy-Induced Neutropenia clinical trials

View clinical trials related to Chemotherapy-Induced Neutropenia.

Filter by:

NCT ID: NCT03102606 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Protective-1
Start date: May 29, 2018
Phase: Phase 3
Study type: Interventional

To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15. *Study is officially closed on 08 Feb 2021*

NCT ID: NCT02787876 Recruiting - Clinical trials for Pediatric Solid Tumor

Pegteograstim in Children With Solid Tumors

Start date: October 4, 2016
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors

NCT ID: NCT02725606 Recruiting - Clinical trials for Chemotherapy-induced Neutropenia

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Start date: March 2016
Phase: Phase 1
Study type: Interventional

The purpose of the present trial is to evaluate the safety, tolerability and pharmacokinetics(PK)/pharmacodynamics(PD) of single subcutaneous injection of GW003 in breast cancer patients. Moreover, the efficacy will be assessed preliminary.

NCT ID: NCT02700360 Completed - Clinical trials for Chemotherapy-Induced Neutropenia

Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers

Start date: August 2015
Phase: Phase 1
Study type: Interventional

A Randomized, Open-Label, Single -Dose, Crossover, Phase I Clinical Trial to Evaluate the Effect of Food on the Safety, Tolerability and Pharmacokinetics of EC-18 after Oral Administration in Healthy Volunteers

NCT ID: NCT02692742 Completed - Breast Cancer Clinical Trials

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

MyeloConcept
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection. Myelo001, a small orally bioavailable molecule, has been shown in chemotherapy- or radiotherapy-induced myelosuppression to stimulate differentiation of peripheral white blood cells (WBC) and bone marrow cells of the leucocytic, lymphocytic, and erythrocytic lineage. The purpose of the MyeloConcept study is to determine the safety and effectiveness of Myelo001 in preventing or reducing chemotherapy-induced neutropenia and myelosuppression in patients receiving chemotherapy due to breast cancer.

NCT ID: NCT02643901 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects

Start date: September 2015
Phase: Phase 1
Study type: Interventional

This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) of single subcutaneous (SC) injection of GW003 in healthy subjects.

NCT ID: NCT02532712 Completed - Clinical trials for Chemotherapy-Induced Neutropenia

Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

Start date: March 2015
Phase: Phase 1
Study type: Interventional

This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and pharmacokinetics of single-dose and multiple-dose oral administration of the investigational product, EC-18 (study drug) in healthy adult male volunteers.

NCT ID: NCT02496143 Completed - Clinical trials for Chemotherapy-induced Neutropenia

A Safety and PK Study of EC-18 in Healthy Subjects

Start date: July 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if EC-18 is safe and tolerable in healthy subjects.

NCT ID: NCT02465801 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein

Start date: December 16, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dosages of recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein by injection for preventing neutrophilic granulocytopenia among chemotherapy patients. Conduct Pharmacokinetics (PK) study on recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein with recombinant human granulocyte colony-stimulating factor injection as a control.

NCT ID: NCT02454530 Terminated - Clinical trials for Chemotherapy-Induced Neutropenia

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

VISTA
Start date: September 2014
Phase:
Study type: Observational

The aim of this study is to describe in real-life conditions the determinants of use of GCSF (Granulocyte Colony-Stimulating Factor) Nivestim® in primary or secondary prophylaxis and in patients receiving chemotherapy for solid tumour according to the chemotherapy context: adjuvant or metastatic setting.